The DOI matches its Crossref record; 78 of the 78 references it cites were found in a registry or an index.
Targeting multiple signal transduction pathways through inhibition of Hsp90
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
Mutations of the BRAF gene in human cancer
Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., et al. (2002) · Nature · doi:10.1038/nature00766 · Cited by 10,674
The phosphatidylinositol 3-Kinase–AKT pathway in human cancer
Vivanco, I., & Sawyers, C. L. (2002) · Nature Reviews Cancer · doi:10.1038/nrc839 · Cited by 6,056
Phosphorylation meets ubiquitination: the control of NF-κB activity
Karin, M., & Ben-Neriah, Y. (2000) · Annual Review of Immunology · doi:10.1146/annurev.immunol.18.1.621 · Cited by 4,766
Wilhelm, S. M., Carter, C., Tang, L., Wilkie, D., McNabola, A., Rong, H., Chen, C., Zhang, X., Vincent, P., McHugh, M., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1443 · Cited by 4,017
Polakis, P. (2000) · Genes & Development · doi:10.1101/gad.14.15.1837 · Cited by 3,183
Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification
Gorre, M. E., Mohammed, M., Ellwood, K., Hsu, N., Paquette, R., Rao, P. N., & Sawyers, C. L. (2001) · Science · doi:10.1126/science.1062538 · Cited by 3,104
Bowman, T., Garcia, R., Turkson, J., & Jove, R. (2000) · Oncogene · doi:10.1038/sj.onc.1203527 · Cited by 1,743
Whitesell, L., Mimnaugh, E. G., De Costa, B., Myers, C. E., & Neckers, L. M. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.18.8324 · Cited by 1,444
A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors
Kamal, A., Thao, L., Sensintaffar, J., Zhang, L., Boehm, M. F., Fritz, L. C., & Burrows, F. J. (2003) · Nature · doi:10.1038/nature01913 · Cited by 1,387
Self-citationStebbins, C. E., Russo, A. A., Schneider, C., Rosen, N., Hartl, F. U., & Pavletich, N. P. (1997) · Cell · doi:10.1016/s0092-8674(00)80203-2 · Cited by 1,364
Prodromou, C., Roe, S. M., O'Brien, R., Ladbury, J. E., Piper, P. W., & Pearl, L. H. (1997) · Cell · doi:10.1016/s0092-8674(00)80314-1 · Cited by 1,265
Roe, S. M., Prodromou, C., O'Brien, R., Ladbury, J. E., Piper, P. W., & Pearl, L. H. (1999) · Journal of Medicinal Chemistry · doi:10.1021/jm980403y · Cited by 1,004
Modulation of Akt kinase activity by binding to Hsp90
Sato, S., Fujita, N., & Tsuruo, T. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.170276797 · Cited by 967
The IκB kinase (IKK) and NF-κB: key elements of proinflammatory signalling
Karin, M., & Delhase, M. (2000) · Seminars in Immunology · doi:10.1006/smim.2000.0210 · Cited by 955
BindingDB (2025) · PubMed · doi:10.7270/q2pc374f · Cited by 924
BRAF Mutation in Papillary Thyroid Carcinoma
Cohen, Y., Xing, M., Mambo, E., Guo, Z., Wu, G., Trink, B., Beller, U., Westra, W. H., Ladenson, P. W., & Sidransky, D. (2003) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/95.8.625 · Cited by 922
The role of FLT3 in haematopoietic malignancies
Stirewalt, D. L., & Radich, J. P. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1169 · Cited by 865
Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin).
Sliwkowski, M. X., Ja, L., Gd, L., Te, H., FENDLY, B. M., & Fox, J. A. (1999) · PubMed · Cited by 653
HEASMAN, J. (1994) · Cell · doi:10.1016/0092-8674(94)90069-8 · Cited by 643
Epling-Burnette, P. K., Liu, J. H., Catlett-Falcone, R., Turkson, J., Oshiro, M., Kothapalli, R., Li, Y., Wang, J.-M., Yang-Yen, H.-F., Karras, J., et al. (2001) · Journal of Clinical Investigation · doi:10.1172/jci9940 · Cited by 633
Basso, A. D., Solit, D. B., Chiosis, G., Giri, B., Tsichlis, P., & Rosen, N. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m206322200 · Cited by 628
HSP90 as a new therapeutic target for cancer therapy: the story unfolds
Maloney, A., & Workman, P. (2002) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2.1.3 · Cited by 531
Marcu, M. G., Chadli, A., Bouhouche, I., Catelli, M., & Neckers, L. M. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m003701200 · Cited by 502
Regulation of the c-Abl and Bcr–Abl tyrosine kinases
Hantschel, O., & Superti-Furga, G. (2004) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1280 · Cited by 487
Schulte, T. W., & Neckers, L. M. (1998) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s002800050817 · Cited by 478
GELDANAMYCIN, A NEW ANTIBIOTIC
DEBOER, C., MEULMAN, P. A., WNUK, R. J., & PETERSON, D. H. (1970) · The Journal of Antibiotics · doi:10.7164/antibiotics.23.442 · Cited by 466
Schulte, T. W., Blagosklonny, M. V., Ingui, C., & Neckers, L. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.41.24585 · Cited by 456
Bianco, R., Shin, I., Ritter, C. A., Yakes, F. M., Basso, A., Rosen, N., Tsurutani, J., Dennis, P. A., Mills, G. B., & Arteaga, C. L. (2003) · Oncogene · doi:10.1038/sj.onc.1206388 · Cited by 448
Targeting mTOR signaling for cancer therapy
Huang, S. (2003) · Current Opinion in Pharmacology · doi:10.1016/s1471-4892(03)00071-7 · Cited by 436
Discovery of a novel Raf kinase inhibitor.
Lyons, J. F., Wilhelm, S., Hibner, B., & Bollag, G. (2001) · Endocrine-related cancer · doi:10.1677/erc.0.0080219 · Cited by 416
Novobiocin and Related Coumarins and Depletion of Heat Shock Protein 90-Dependent Signaling Proteins
Marcu, M. G., Schulte, T. W., & Neckers, L. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.242 · Cited by 405
Schulte, T. W., Akinaga, S., Soga, S., Sullivan, W., Stensgard, B., Toft, D., & Neckers, L. M. (1998) · Cell Stress & Chaperones · doi:10.1379/1466-1268(1998)003<0100:arbttn>2.3.co;2 · Cited by 403
Neckers, L., & Ivy, S. P. (2003) · Current Opinion in Oncology · doi:10.1097/00001622-200311000-00003 · Cited by 400
TNF-Induced Recruitment and Activation of the IKK Complex Require Cdc37 and Hsp90
Chen, G., Cao, P., & Goeddel, D. V. (2002) · Molecular Cell · doi:10.1016/s1097-2765(02)00450-1 · Cited by 400
Xu, W., Mimnaugh, E., Rosser, M. F. N., Nicchitta, C., Marcu, M., Yarden, Y., & Neckers, L. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m006864200 · Cited by 353
Expression of the hematopoietic growth factor receptor FLT3 (STK- 1/Flk2) in human leukemias
Carow, C., Levenstein, M., Kaufmann, S., Chen, J., Amin, S., Rockwell, P., Witte, L., Borowitz, M., Civin, C., & Small, D. (1996) · Blood · doi:10.1182/blood.v87.3.1089.bloodjournal8731089 · Cited by 345
Differential molecular interactions of β-catenin and plakoglobin in adhesion, signaling and cancer
Ben-Ze'ev, A., & Geiger, B. (1998) · Current Opinion in Cell Biology · doi:10.1016/s0955-0674(98)80039-2 · Cited by 341
Solit, D. B., Basso, A. D., Olshen, A. B., Scher, H. I., & Rosen, N. X. (2003) · PubMed · Cited by 307
Wilhelm, S., & Chien, D.-S. (2002) · Current Pharmaceutical Design · doi:10.2174/1381612023393026 · Cited by 289
Chiosis, G., Timaul, M. N., Lucas, B., Munster, P. N., Zheng, F. F., Sepp-Lorenzino, L., & Rosen, N. (2001) · Chemistry & Biology · doi:10.1016/s1074-5521(01)00015-1 · Cited by 288
Targeting of the protein chaperone, HSP90, by the transformation suppressing agent, radicicol
Sharma, S. V., Agatsuma, T., & Nakano, H. (1998) · Oncogene · doi:10.1038/sj.onc.1201790 · Cited by 277
Schulte, T. W., Blagosklonny, M. V., Romanova, L., Mushinski, J. F., Monia, B. P., Johnston, J. F., Nguyen, P., Trepel, J., & Neckers, L. M. (1996) · Molecular and Cellular Biology · doi:10.1128/mcb.16.10.5839 · Cited by 269
Basso, A. D., Solit, D. B., Munster, P. N., & Rosen, N. (2002) · Oncogene · doi:10.1038/sj.onc.1205184 · Cited by 265
Structure and Functional Relationships of Hsp90
Prodromou, C., & Pearl, L. (2003) · Current Cancer Drug Targets · doi:10.2174/1568009033481877 · Cited by 261
Rosnet, O., Bühring, H. ‐., Marchetto, S., Rappold, I., Lavagna, C., Sainty, D., Arnoulet, C., Chabannon, C., Kanz, L., Hannum, C. H., et al. (1996) · PubMed · Cited by 245
Nimmanapalli, R., O’Bryan, E., & Bhalla, K. N. (2001) · PubMed · Cited by 242
Uehara, Y., Hori, M., Takeuchi, T., & Umezawa, H. (1986) · Molecular and Cellular Biology · doi:10.1128/mcb.6.6.2198 · Cited by 233
Enhanced sensitivity of multiple myeloma cells containing PTEN mutations to CCI-779.
Shi, Y., Gera, J., Hu, L., Hsu, J.-H., Bookstein, R., Li, W., & Lichtenstein, A. K. (2002) · PubMed · Cited by 231
Gorre, M. E., Ellwood-Yen, K., Chiosis, G., Rosen, N., & Sawyers, C. L. (2002) · Blood · doi:10.1182/blood-2002-05-1361 · Cited by 227
Clinical Development of 17-Allylamino, 17-Demethoxygeldanamycin
Sausville, E., Tomaszewski, J., & Ivy, P. (2003) · Current Cancer Drug Targets · doi:10.2174/1568009033481831 · Cited by 225
Mechanism of Action of Anti-Her2 Monoclonal Antibodies: Scientific Update on Trastuzumab and 2c4
Albanell, J., Codony, J., Rovira, A., Mellado, B., & Gascón, P. (2003) · Advances in Experimental Medicine and Biology · doi:10.1007/978-1-4615-0081-0_21 · Cited by 219
A Nucleotide-dependent Molecular Switch Controls ATP Binding at the C-terminal Domain of Hsp90
Söti, C., Rácz, A., & Csermely, P. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m105568200 · Cited by 212
Involvement of Hsp90 in Signaling and Stability of 3-Phosphoinositide-dependent Kinase-1
Fujita, N., Sato, S., Ishida, A., & Tsuruo, T. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m106736200 · Cited by 198
Chiosis, G., Lucas, B., Shtil, A., Huezo, H., & Rosen, N. (2002) · Bioorganic & Medicinal Chemistry · doi:10.1016/s0968-0896(02)00253-5 · Cited by 195
Citri, A., Kochupurakkal, B. S., & Yarden, Y. (2004) · Cell Cycle · doi:10.4161/cc.3.1.607 · Cited by 174
Regulation of β-Catenin Function by the IκB Kinases
Lamberti, C., Lin, K., Yamamoto, Y., Verma, U. N., Verma, I. M., Byers, S., & Gaynor, R. B. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m104227200 · Cited by 165
ATPases as drug targets: learning from their structure
Chène, P. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd894 · Cited by 163
Interaction of Radicicol with Members of the Heat Shock Protein 90 Family of Molecular Chaperones
Schulte, T. W. (1999) · Molecular Endocrinology · doi:10.1210/me.13.9.1435 · Cited by 161
Ménard, S., Casalini, P., Campiglio, M., Pupa, S. M., Agresti, R., & Tagliabue, E. (2001) · Annals of Oncology · doi:10.1093/annonc/12.suppl_1.s15 · Cited by 149
Activating mutations of RTK/ras signal transduction pathway in pediatric acute myeloid leukemia
Meshinchi, S., Stirewalt, D. L., Alonzo, T. A., Zhang, Q., Sweetser, D. A., Woods, W. G., Bernstein, I. D., Arceci, R. J., & Radich, J. P. (2003) · Blood · doi:10.1182/blood-2003-01-0137 · Cited by 146
Soga, S., Neckers, L. M., Schulte, T. W., Shiotsu, Y., Akasaka, K., Narumi, H., Agatsuma, T., IKUINA, Y., Murakata, C., Tamaoki, T., et al. (1999) · PubMed · Cited by 133
Nimmanapalli, R., O’Bryan, E., Huang, M., Bali, P., Burnette, P. K., Loughran, T. P., Tepperberg, J. H., Jove, R., & Bhalla, K. N. (2002) · PubMed · Cited by 125
Yao, Q., Nishiuchi, R., Li, Q., Kumar, A. R., Hudson, W. A., & Kersey, J. H. (2003) · PubMed · Cited by 111
Shiotsu, Y., Neckers, L. Μ., Wortman, I. A., An, W. G., Schulte, T. W., Soga, S., Murakata, C., Tamaoki, T., & Akinaga, S. (2000) · Blood · doi:10.1182/blood.v96.6.2284 · Cited by 102
Involvement of heat-shock protein 90 in the interleukin-6-mediated signaling pathway through STAT3
Sato, N., Yamamoto, T., Sekine, Y., Yumioka, T., Junicho, A., Fuse, H., & Matsuda, T. (2003) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(02)02941-8 · Cited by 95
Jaiswal, R. K., Weissinger, E. M., Kölch, W., & Landreth, G. E. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.39.23626 · Cited by 90
Bagrintseva, K., Schwab, R., Kohl, T. M., Schnittger, S., Eichenlaub, S., Ellwart, J. W., Hiddemann, W., & Spiekermann, K. (2003) · Blood · doi:10.1182/blood-2003-05-1653 · Cited by 85
A novel chaperone-activity-reducing mechanism of the 90-kDa molecular chaperone HSP90
Itoh, H., Ogura, M., Komatsuda, A., Wakui, H., MIURA, A. B., & Tashima, Y. (1999) · Biochemical Journal · doi:10.1042/bj3430697 · Cited by 83
Clinical development of mammalian target of rapamycin inhibitors
Dancey, J. E. (2002) · Hematology/Oncology Clinics of North America · doi:10.1016/s0889-8588(02)00051-5 · Cited by 81
Nguyen, D. M., Lorang, D., Chen, G. A., Stewart, J. H., Tabibi, E., & Schrump, D. S. (2001) · The Annals of Thoracic Surgery · doi:10.1016/s0003-4975(01)02787-4 · Cited by 78
Radicicol, an Agent Inducing the Reversal of Transformed Phenotypes ofsrc-Transformed Fibroblasts
Kwon, H. J., Yoshida, M., Abe, K., et al. (1992) · Bioscience Biotechnology and Biochemistry · doi:10.1271/bbb.56.538 · Cited by 68
Dymock, B. W., Barril, X., Beswick, M., Collier, A. J., Davies, N., Drysdale, M., Fink, A., Fromont, C., Hubbard, R. E., Massey, A. J., et al. (2003) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2003.11.011 · Cited by 68
Stereospecific antitumor activity of radicicol oxime derivatives
Soga, S., Sharma, S. V., Shiotsu, Y., Shimizu, M., Tahara, H., Yamaguchi, K., Ikuina, Y., Murakata, C., Tamaoki, T., Kurebayashi, J., et al. (2001) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s002800100373 · Cited by 59
Suppression of RAS and MOS transformation by radicicol.
Zhao, J., Nakano, H., & Sharma, S. V. (1995) · PubMed · Cited by 48
Imatinib: A targeted clinical drug development
Capdeville, R., & Silberman, S. (2003) · Seminars in Hematology · doi:10.1016/s0037-1963(03)70015-8 · Cited by 26
Inhibiting Tyrosine Kinases: Successes and Limitations
Arteaga, C. L. (2003) · Cancer Biology & Therapy · doi:10.4161/cbt.206 · Cited by 20
Liu, S. M., & Carpenter, G. F. (1993) · Journal of Cellular Physiology · doi:10.1002/jcp.1041570205 · Cited by 8
Cited by
Nuclear Lamin-A Scales with Tissue Stiffness and Enhances Matrix-Directed Differentiation
Swift, J., Ivanovska, I. L., Buxboim, A., Harada, T., Dingal, P. C. D. P., Pinter, J., Pajerowski, J. D., Spinler, K. R., Shin, J.-W., Tewari, M., et al. (2013) · Science · doi:10.1126/science.1240104 · Cited by 1,991
Mechanisms of Disease: understanding resistance to HER2-targeted therapy in human breast cancer
Nahta, R., Yu, D., Hung, M.-C., Hortobagyi, G. N., & Esteva, F. J. (2006) · Nature Clinical Practice Oncology · doi:10.1038/ncponc0509 · Cited by 916
WORKMAN, P., BURROWS, F., NECKERS, L., & ROSEN, N. (2007) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1391.012 · Cited by 521
Self-citationKemp, J. A., Shim, M. S., Heo, C. Y., & Kwon, Y. J. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2015.10.019 · Cited by 506
Heat shock proteins: essential proteins for apoptosis regulation
Lanneau, D., Brunet, M., Frisan, E., Solary, E., Fontenay, M., & Garrido, C. (2008) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2008.00273.x · Cited by 501
Metadata
- Authors
- Zhang, H., & Burrows, F.
- Venue
- Journal of Molecular Medicine
- Published
- 2004-05-27
- Volume
- 82
- Issue
- 8
- Pages
- 488-99
- ISSN
- 0946-2716 (ISSN-L)
- 1432-1440
- OpenAlex
- W1971190195
- Cited by
- 377
- References
- 78
- FWCI
- 7.33
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.